Kennel club

Kennel club

The capital market and health care environments are putting a premium on the ability of biotech companies to rethink their business strategies to fit the times. Except for a lucky few, companies of the class of '91-92 that grew up with the fully integrated biopharmaceutical company (Fibco) model risk being left behind.

One company that isn't waiting is Glycomed Inc., which on Friday

Read the full 647 word article

How to gain access

Continue reading with a
two-week free trial.